NASDAQ · KLTO
Klotho Neurosciences, Inc.
$0.52 +$0.00 (+0.81%) 1DKey Metrics
$25.14M
Market cap
—
P/E · TTM
—
Revenue · TTM
—
Net income
EPS · TTM
—
Dividend yield
—
Free cash flow
—
Beta · 1Y
2.97
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap$25.14M
Enterprise value—
Shares outstanding72.5M
52-wk range$0.21 – $1.23
Avg volume · 20D8.4M
Net cash
—
Book value / share—
IndustryBiological Products, (No Disgnostic Substances)
ExchangeNASDAQ
About Klotho Neurosciences, Inc.
IPO dateJun 24, 2024
Employees3
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
— · —
Financial Health
Current ratio—
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital—
Cash Flow · TTM
Operating CF
—
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
—
Needs two fiscal years of filings
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value